-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Thursday’s Vital Data: Bristol-Myers Squibb, Cronos and Canopy Growth
Options trading was hot in Bristol-Myers Squibb, Cronos and Canopy Growth stock on Tuesday. Here’s what the data suggests moving forward.
Aurora Stock Will Have Another Rough Year
The shaky financials of Aurora stock make ACB stock one of the worst choices in the marijuana industry.
There’s No World Where ACB Stock Plummets to Nothing
One analyst recently made a bold prediction that ACB stock is completely worthless. While Aurora remains an extremely risky bet, the stock will never make it to $0.
Is Canopy Growth a Worthy Investment in 2020?
Canopy Growth has been hammered in 2019, along with the the rest of the cannabis space. Is a rebound ready to go?
Why We Had to Add This Stock to Our 2020 “Screaming Buy” List
Our research and analysis have identified another name in biotech stocks with big potential in 2020.
Here’s Why You Should Pay More, Not Less for Aphria Stock
Aphria stock is already delivering on the bottom line for its shareholders. It's also shaping up to deliver big profits in 2020.
Avoid Aurora Cannabis As Shares Have No Fight Left
The cannabis space is struggling, and making investments in this area is speculative. With that said, Aurora Cannabis acts too bad to touch.
Can Canopy Growth Rise Above the Cannabis Industry’s Reputation?
The cannabis industry suffered horribly in 2019 and Aurora Cannabis’ controversial executive departure creates a trust issue for Canopy Growth and other major players.
U.S. Cannabis Stocks Will Make Cheap, Smart Buys in 2020
Matt McCall predicts that 2020 will be a better year for U.S. cannabis stocks. He's also calling for a big rally in bitcoin.
Is Aphria the Best Cannabis Stock to Buy?
Aphria stock has some of the best financials in the cannabis space, but that hasn't stopped APHA stock from getting hit like its peers.
Why Aurora Cannabis Should See a Turn for the Better in 2020
Aurora is ending the year on a sour note, but could be setting up for a much better 2020. Here’s a look at three key factors for the bull case.
Make Aurora Cannabis Front and Center in Your Pot-folio
Ignore the haters. Aurora Cannabis isn't headed to zero anytime soon. In fact it might just become the cannabis market's hero in 2020.
Canopy Growth Could Surprise in 2020, but Don’t Rush In
With strong capitalization, Canopy Growth is a "safer" pot stock play. But to tilt the odds in your favor, take your time before buying.
Embattled TEVA Has Made Headlines for All of the Wrong Reasons
Teva Pharmaceuticals is under the glare of legal and regulatory scrutiny. However, TEVA will eventually find its way because frankly, it has to.
Hexo Hoping to Recover With Cannabis 2.0 Boom in 2020
With Cannabis 2.0 in the works, Hexo’s risk-reward profile is beginning to look very favorable for investors willing to stick their necks out. Here’s why.
Aurora Stock Dove After an Analyst Gave It a $0 Price Target
Aurora stock took another hit on Monday after a research analyst set a $0 price target on ACB stock, citing high debt and high supply.
Why Canopy Growth Stock is a Buy Today as Cannabis’ Bad Year Nears End
It’s unlikely to be the next Netflix or Microsoft, but Canopy Growth stock has made the case for today’s investors to take a nibble
Amarin Stock is at Sky-High Levels Already Assumes All the Good News
Amarin stock is at sky high levels assuming all the good news. The FDA drug approval was anticipated and the AMRN stock price had implied it already.
